{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:15:55Z","timestamp":1771888555610,"version":"3.50.1"},"reference-count":75,"publisher":"Walter de Gruyter GmbH","issue":"10","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over 3% of asthmatic patients are affected by a particularly severe form of the disease (\u201csevere asthma\u201d, SA) which is often refractory to standard treatment. Airway remodeling (AR), which can be considered a critical characteristic of approximately half of all patients with SA and currently thought to be the main mechanism triggering fixed airway obstruction (FAO), seems to be a key factor affecting a patient\u2019s outcome. Despite the collective efforts of internationally renowned experts, to date only a few biomarkers indicative of AR and no recognizable biomarkers of lung parenchymal remodeling have been identified. This work examines the pathogenesis of airway and lung parenchymal remodeling and the serum biomarkers that may be able to identify the severe asthmatic patients who may develop FAO. The study also aims to examine if Krebs von den Lungen-6 (KL-6) could be considered a diagnostic biomarker of lung structural damage in SA.<\/jats:p>","DOI":"10.1515\/cclm-2022-1323","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T21:51:15Z","timestamp":1680126675000},"page":"1679-1687","source":"Crossref","is-referenced-by-count":12,"title":["Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6"],"prefix":"10.1515","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-6029","authenticated-orcid":false,"given":"Andrea","family":"Vianello","sequence":"first","affiliation":[{"name":"Department of Cardiac Thoracic Vascular Sciences and Public Health , University of Padova , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Guarnieri","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic Vascular Sciences and Public Health , University of Padova , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Achille","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic Vascular Sciences and Public Health , University of Padova , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Lionello","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic Vascular Sciences and Public Health , University of Padova , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lococo","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic Vascular Sciences and Public Health , University of Padova , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Zaninotto","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , University-Hospital of Padova , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[{"name":"Asthma Center and Allergy Unit, University of Verona , Verona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[{"name":"Asthma Center and Allergy Unit, University of Verona , Verona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"2024012315074075255_j_cclm-2022-1323_ref_001","doi-asserted-by":"crossref","unstructured":"Vianello, A, Caminati, M, Andretta, M, Menti, AM, Tognella, S, Senna, G, et al.. Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience. World Allergy Organ J 2019;12:100032. https:\/\/doi.org\/10.1016\/j.waojou.2019.100032.","DOI":"10.1016\/j.waojou.2019.100032"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_002","doi-asserted-by":"crossref","unstructured":"Holguin, F, Cardet, JC, Chung, KF, Diver, S, Ferreira, DS, Fitzpatrick, A, et al.. Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline. Eur Respir J 2020;55:55. https:\/\/doi.org\/10.1183\/13993003.00588-2019.","DOI":"10.1183\/13993003.00588-2019"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_003","doi-asserted-by":"crossref","unstructured":"Chiappori, A, De Ferrari, L, Folli, C, Mauri, P, Riccio, AM, Canonica, GW. Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy 2015;13:20. https:\/\/doi.org\/10.1186\/s12948-015-0027-7.","DOI":"10.1186\/s12948-015-0027-7"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_004","doi-asserted-by":"crossref","unstructured":"McGregor, MC, Krings, JG, Nair, P, Castro, M. Role of biologics in asthma. Am J Respir Crit Care Med 2019;199:433\u20135. https:\/\/doi.org\/10.1164\/rccm.201810-1944ci.","DOI":"10.1164\/rccm.201810-1944CI"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_005","doi-asserted-by":"crossref","unstructured":"Wenzel, SE. Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med 2021;203:809\u201321. https:\/\/doi.org\/10.1164\/rccm.202009-3631ci.","DOI":"10.1164\/rccm.202009-3631CI"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_006","doi-asserted-by":"crossref","unstructured":"Bai, TR, Knight, DA. Structural changes in the airways in asthma: observations and consequences. Clin Sci (Lond) 2005;108:463\u201377. https:\/\/doi.org\/10.1042\/CS20040342.","DOI":"10.1042\/CS20040342"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_007","doi-asserted-by":"crossref","unstructured":"Varricchi, G, Ferri, S, Pepys, J, Poto, R, Spadaro, G, Nappi, E, et al.. Biologics and airway remodeling in severe asthma. Allergy 2022;77:3538\u201352. https:\/\/doi.org\/10.1111\/all.15473.","DOI":"10.1111\/all.15473"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_008","doi-asserted-by":"crossref","unstructured":"Fehrenbach, H, Wagner, C, Wegmann, M. Airway remodeling in asthma: what really matters. Cell Tissue Res 2017;367:551\u201369. https:\/\/doi.org\/10.1007\/s00441-016-2566-8.","DOI":"10.1007\/s00441-016-2566-8"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_009","doi-asserted-by":"crossref","unstructured":"Huang, Y, Qiu, C. Research advances in airway remodeling in asthma: a narrative review. Ann Transl Med 2022;10:1023. https:\/\/doi.org\/10.21037\/atm-22-2835.","DOI":"10.21037\/atm-22-2835"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_010","doi-asserted-by":"crossref","unstructured":"Shikotra, A, Choy, DF, Siddiqui, S, Arthur, G, Nagarkar, DR, Jia, G, et al.. A CEACAM6-high airway neutrophil phenotype and CEACAM6-high epithelial cells are features of severe asthma. J Immunol 2017;198:3307\u201317. https:\/\/doi.org\/10.4049\/jimmunol.1600606.","DOI":"10.4049\/jimmunol.1600606"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_011","doi-asserted-by":"crossref","unstructured":"Salter, B, Pray, C, Radford, K, Martin, JG, Nair, P. Regulation of human airway smooth muscle cell migration and relevance to asthma. Respir Res 2017;18:156. https:\/\/doi.org\/10.1186\/s12931-017-0640-8.","DOI":"10.1186\/s12931-017-0640-8"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_012","doi-asserted-by":"crossref","unstructured":"Hong, H, Liao, S, Chen, F, Yang, Q, Wang, DY. Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type2 inflammation. Allergy 2020;75:2794\u2013804. https:\/\/doi.org\/10.1111\/all.14526.","DOI":"10.1111\/all.14526"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_013","doi-asserted-by":"crossref","unstructured":"Wang, W, Li, Y, Lv, Z, Chen, Y, Li, Y, Huang, K, et al.. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa. J\u00a0Immunol 2018;201:2221\u201331. https:\/\/doi.org\/10.4049\/jimmunol.1800709.","DOI":"10.4049\/jimmunol.1800709"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_014","doi-asserted-by":"crossref","unstructured":"Cai, LM, Zhou, YQ, Yang, LF, Qu, JX, Dai, ZH, Li, HT, et al.. Thymic stromal lymphopoietin induced early stage of epithelial-mesenchymal transition in human bronchial epithelial cells through upregulation of transforming growth factor beta 1. Exp Lung Res 2019;45:221\u201335. https:\/\/doi.org\/10.1080\/01902148.2019.1646841.","DOI":"10.1080\/01902148.2019.1646841"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_015","doi-asserted-by":"crossref","unstructured":"Toki, S, Goleniewska, K, Zhang, J, Zhou, W, Newcomb, DC, Zhou, B, et al.. TSLP and IL-33 reciprocally promote each other\u2019s lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation. Allergy 2020;75:1606\u201317. https:\/\/doi.org\/10.1111\/all.14196.","DOI":"10.1111\/all.14196"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_016","doi-asserted-by":"crossref","unstructured":"Tukler Henriksson, J, Coursey, TG, Corry, DB, De Paiva, CS, Pflugfelder, SC. IL13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci 2015;56:4186\u201397. https:\/\/doi.org\/10.1167\/iovs.14-15496.","DOI":"10.1167\/iovs.14-15496"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_017","doi-asserted-by":"crossref","unstructured":"Doherty, T, Broide, D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007;19:676\u201380. https:\/\/doi.org\/10.1016\/j.coi.2007.07.017.","DOI":"10.1016\/j.coi.2007.07.017"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_018","doi-asserted-by":"crossref","unstructured":"Chetta, A, Zanini, A, Foresi, A, Del Donno, M, Castagnaro, A, D\u2019Ippolito, R, et al.. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003;167:751\u20137. https:\/\/doi.org\/10.1164\/rccm.200207-710OC.","DOI":"10.1164\/rccm.200207-710OC"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_019","doi-asserted-by":"crossref","unstructured":"Xu, X, Luo, S, Li, B, Dai, H, Zhang, J. IL-25 contributes to lung fibrosis by directly acting on alveolar epithelial cells and fibroblasts. Exp Biol Med (Maywood) 2019;244:770\u201380. https:\/\/doi.org\/10.1177\/1535370219843827.","DOI":"10.1177\/1535370219843827"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_020","doi-asserted-by":"crossref","unstructured":"Liu, G, Cooley, MA, Nair, PM, Donovan, C, Hsu, AC, Jarnicki, AG, et al.. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c. J Pathol 2017;243:510\u201323. https:\/\/doi.org\/10.1002\/path.4979.","DOI":"10.1002\/path.4979"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_021","doi-asserted-by":"crossref","unstructured":"Bai, TR, Knight, DA. Structural changes in the airways in asthma: observations and consequences. Clin Sci (Lond) 2005;108:463\u201377. https:\/\/doi.org\/10.1042\/CS20040342.","DOI":"10.1042\/CS20040342"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_022","doi-asserted-by":"crossref","unstructured":"Shipe, R, Burdick, MD, Strieter, BA, Liu, L, Shim, YM, Sung, SS, et al.. Number, activation, and differentiation of circulating fibrocytes correlate with asthma severity. J Allergy Clin Immunol 2016;37:750\u20137.e3. https:\/\/doi.org\/10.1016\/j.jaci.2015.07.037.","DOI":"10.1016\/j.jaci.2015.07.037"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_023","doi-asserted-by":"crossref","unstructured":"Bai, TR, Cooper, J, Koelmeyer, T, Pare, PD, Weir, T. The effect of age and duration of disease on airway structure in fatal asthma. Am J Respir Crit Care Med 2000;162:663\u20139. https:\/\/doi.org\/10.1164\/ajrccm.162.2.9907151.","DOI":"10.1164\/ajrccm.162.2.9907151"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_024","doi-asserted-by":"crossref","unstructured":"Fehrenbach, H, Wagner, C, Wegmann, M. Airway remodeling in asthma: what really matters. Cell Tissue Res 2017;367:551\u201369. https:\/\/doi.org\/10.1007\/s00441-016-2566-8.","DOI":"10.1007\/s00441-016-2566-8"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_025","doi-asserted-by":"crossref","unstructured":"Graham, BL, Steenbruggen, I, Miller, MR, Barjaktarevic, IZ, Cooper, BG, Hall, GL, et al.. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70\u201388. https:\/\/doi.org\/10.1164\/rccm.201908-1590st.","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_026","doi-asserted-by":"crossref","unstructured":"Lee, JH, Haselkorn, T, Borish, L, Rasouliyan, L, Chipps, BE, Wenzel, SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma. Chest 2007;132:1882\u20139. https:\/\/doi.org\/10.1378\/chest.07-0713.","DOI":"10.1378\/chest.07-0713"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_027","doi-asserted-by":"crossref","unstructured":"Boulet, LP. Airway remodeling in asthma: update on mechanisms and therapeutic approaches. Curr Opin Pulm Med 2018;24:56\u201362. https:\/\/doi.org\/10.1097\/MCP.0000000000000441.","DOI":"10.1097\/MCP.0000000000000441"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_028","doi-asserted-by":"crossref","unstructured":"Ferreira, DS, Carvalho-Pinto, RM, Greg\u00f3rio, MG, Annoni, R, Teles, AM, Buttignol, M, et al.. Airway pathology in severe asthma Is related to airflow obstruction but not symptom control. Allergy 2018;73:635\u201343. https:\/\/doi.org\/10.1111\/all.13323.","DOI":"10.1111\/all.13323"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_029","doi-asserted-by":"crossref","unstructured":"Smith, BM, Zhao, N, Olivenstein, R, Lemiere, C, Hamid, Q, Martin, JG. Asthma and fixed airflow obstruction: long-term trajectories suggest distinct endotypes. Clin Exp Allergy 2021;51:39\u201348. https:\/\/doi.org\/10.1111\/cea.13714.","DOI":"10.1111\/cea.13714"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_030","doi-asserted-by":"crossref","unstructured":"Shimizu, K, Tanabe, N, Oguma, A, Nishimura, M, Suzuki, M, Yokota, I, et al.. Konno S for the Hi-CARAT investigators. Parenchymal destruction in asthma: fixed airflow obstruction and lung function trajectory. J Allergy Clin Immunol 2022;149:934\u201342.e8. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.042.","DOI":"10.1016\/j.jaci.2021.07.042"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_031","doi-asserted-by":"crossref","unstructured":"Gao, P, Gibson, PG, Baines, KJ, Yang, IA, Upham, JW, Reynolds, PN, et al.. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA\/IL-1\u03b2. Respir Res 2015;24:5. https:\/\/doi.org\/10.1186\/s12931-014-0163-5.","DOI":"10.1186\/s12931-014-0163-5"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_032","doi-asserted-by":"crossref","unstructured":"Riccio, AM, Mauri, P, De Ferrari, L, Rossi, R, Di Silvestre, D, Benazzi, L, et al.. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36\u00a0months. Clin Transl Allergy 2017;7:6. https:\/\/doi.org\/10.1186\/s13601-017-0143-1.","DOI":"10.1186\/s13601-017-0143-1"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_033","doi-asserted-by":"crossref","unstructured":"Riccio, AM, Mauri, P, De Ferrari, L, Rossi, R, Di Silvestre, D, Bartezaghi, M, et al.. Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: results from the PROXIMA sub-study. World Allergy Organ J 2020;13:100095. https:\/\/doi.org\/10.1016\/j.waojou.2019.100095.","DOI":"10.1016\/j.waojou.2019.100095"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_034","doi-asserted-by":"crossref","unstructured":"Chupp, GL, Lee, CG, Jarjour, N, Shim, YM, Holm, CT, He, S, et al.. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007;357:2016\u201327. https:\/\/doi.org\/10.1056\/NEJMoa073600.","DOI":"10.1056\/NEJMoa073600"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_035","doi-asserted-by":"crossref","unstructured":"Ilmarinen, P, Tuomisto, LE, Niemel\u00e4, O, H\u00e4m\u00e4l\u00e4inen, M, Moilanen, E, Kankaanrnta, H. YKL-40 and adult-onset asthma: elevated levels in clusters with poorest outcome. J Allergy Clin Immunol Pract 2019;7:2466\u20138.e3. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.043.","DOI":"10.1016\/j.jaip.2019.03.043"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_036","doi-asserted-by":"crossref","unstructured":"Tang, H, Sun, Y, Shi, Z, Huang, H, Fang, Z, Chen, J, et al.. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-kappaB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol 2013;190:438\u20134. https:\/\/doi.org\/10.4049\/jimmunol.1201827.","DOI":"10.4049\/jimmunol.1201827"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_037","doi-asserted-by":"crossref","unstructured":"Kimura, H, Shimizu, K, Tanabe, N, Hirai, T, Nishimura, M, Konno, S, et al.. Further evidence for association of YKL-40 with severe asthma airway remodeling. Ann Allergy Asthma Immunol 2022;128:682\u20138.e5. https:\/\/doi.org\/10.1016\/j.anai.2022.03.016.","DOI":"10.1016\/j.anai.2022.03.016"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_038","doi-asserted-by":"crossref","unstructured":"Fouka, E, Domvri, K, Gkakou, F, Alevizaki, M, Steiropoulos, P, Papakosta, D, et al.. Recent insights in the role of biomarkers in severe asthma management. Front Med (Lausanne) 2022;9:992565. https:\/\/doi.org\/10.3389\/fmed.2022.992565.","DOI":"10.3389\/fmed.2022.992565"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_039","doi-asserted-by":"crossref","unstructured":"Takayama, G, Arima, K, Kanaji, T, Toda, S, Tanaka, H, Shoji, S, et al.. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98\u2013104. https:\/\/doi.org\/10.1016\/j.jaci.2006.02.046.","DOI":"10.1016\/j.jaci.2006.02.046"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_040","doi-asserted-by":"crossref","unstructured":"Takahashi, K, Meguro, K, Kawashima, H, Kashiwakuma, D, Kagami, SI, Ohta, S, et al.. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma 2018;56:236\u201343. https:\/\/doi.org\/10.1080\/02770903.2018.145585576.","DOI":"10.1080\/02770903.2018.1455855"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_041","doi-asserted-by":"crossref","unstructured":"Fingleton, J, Braithwaite, I, Travers, J, Bowles, D, Strik, R, Siebers, R, NZRHS Study Group, et al.. Serum periostin in obstructive airways disease. Eur Respir J 2016;47:1383\u201391. https:\/\/doi.org\/10.1183\/13993003.01384-2015.","DOI":"10.1183\/13993003.01384-2015"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_042","doi-asserted-by":"crossref","unstructured":"Hoshino, M, Ohtawa, J, Akitsu, K. Effect of treatment with inhaled corticosteroid on serum periostin levels in asthma. Respirology 2015;21:297\u2013303. https:\/\/doi.org\/10.1111\/resp.12687.","DOI":"10.1111\/resp.12687"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_043","doi-asserted-by":"crossref","unstructured":"Wagener, AH, de Nijs, SB, Lutter, R, Sousa, AR, Weersink, EJ, Bel, EH, et al..\u00a0External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115\u201320. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205634.","DOI":"10.1136\/thoraxjnl-2014-205634"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_044","doi-asserted-by":"crossref","unstructured":"Huang, Y, Wang, L, Jia, X, Lin, X, Zhang, W. Vitamin D alleviates airway remodeling in asthma by down-regulating the activity of Wnt\/\u03b2-catenin signaling pathway. Int Immunopharmacol 2019;68:88\u201394. https:\/\/doi.org\/10.1016\/j.intimp.2018.12.061.","DOI":"10.1016\/j.intimp.2018.12.061"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_045","doi-asserted-by":"crossref","unstructured":"Sobczak, M, Pawliczak, R. Does Vitamin D work synergistically with anti-asthmatic drugs in airway remodeling? Int J Mol Sci 2022;23:12798. https:\/\/doi.org\/10.3390\/ijms232112798.","DOI":"10.3390\/ijms232112798"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_046","doi-asserted-by":"crossref","unstructured":"Zhang, J, Dong, L. Status and prospects: personalized treatment and biomarker for airway remodeling in asthma. J Thorac Dis 2020;12:6090\u2013101. https:\/\/doi.org\/10.21037\/jtd-20-1024.","DOI":"10.21037\/jtd-20-1024"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_047","unstructured":"Crapo, JD, Barry, BE, Gehr, P, Bachofen, M, Weibel, ER. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982;126:332\u20137. https:\/\/doi.org\/10.1164\/arrd.1982.126.2.332."},{"key":"2024012315074075255_j_cclm-2022-1323_ref_048","doi-asserted-by":"crossref","unstructured":"Griese, M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999;13:1455\u201376. https:\/\/doi.org\/10.1183\/09031936.99.13614779.","DOI":"10.1183\/09031936.99.13614779"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_049","doi-asserted-by":"crossref","unstructured":"Ruaro, B, Salton, F, Braga, L, Wade, B, Confalonieri, P, Volpe, MC, et al.. The history and mystery of alveolar epithelial type ii cells: focus on their physiologic and pathologic role in lung. Int J Mol Sci 2021;22:2566. https:\/\/doi.org\/10.3390\/ijms22052566.","DOI":"10.3390\/ijms22052566"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_050","doi-asserted-by":"crossref","unstructured":"Ishizaka, A, Matsuda, T, Albertine, KH, Koh, H, Tasaka, S, Hasegawa, N, et al.. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2004;286:L1088\u201394. https:\/\/doi.org\/10.1152\/ajplung.00420.2002.","DOI":"10.1152\/ajplung.00420.2002"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_051","doi-asserted-by":"crossref","unstructured":"Rutting, S, Thamrin, C, Cross, TJ, King, GG, Tonga, KO. Fixed airflow obstruction in asthma: a problem of the whole lung not of just the airways. Front Physiol 2022;13:898208. https:\/\/doi.org\/10.3389\/fphys.2022.898208.","DOI":"10.3389\/fphys.2022.898208"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_052","doi-asserted-by":"crossref","unstructured":"Gelb, AF, Zamel, N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000;162:1778\u201382. https:\/\/doi.org\/10.1164\/ajrccm.162.5.2001037.","DOI":"10.1164\/ajrccm.162.5.2001037"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_053","doi-asserted-by":"crossref","unstructured":"Mauad, T, Silva, LFF, Santos, MA, Grinberg, L, Bernardi, FDC, Martins, MA, et al.. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004;170:857\u201362. https:\/\/doi.org\/10.1164\/rccm.200403-305oc.","DOI":"10.1164\/rccm.200403-305OC"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_054","doi-asserted-by":"crossref","unstructured":"Kraft, M, Martin, RJ, Wilson, S, Djukanovic, R, Holgate, ST. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999;159:228\u201334. https:\/\/doi.org\/10.1164\/ajrccm.159.1.9804033.","DOI":"10.1164\/ajrccm.159.1.9804033"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_055","doi-asserted-by":"crossref","unstructured":"Olajuyin, AM, Zhang, X, Ji, H-L. Alveolar type 2 progenitor cells for lung injury repair. Cell Death Discov 2019;5:63. https:\/\/doi.org\/10.1038\/s41420-019-0147-9.","DOI":"10.1038\/s41420-019-0147-9"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_056","doi-asserted-by":"crossref","unstructured":"Gelb, AF, Yamamoto, A, Verbeken, EK, Schein, MJ, Moridzadeh, R, Tran, D, et al.. Further studies of unsuspected emphysema in nonsmoking patients with asthma with persistent expiratory airflow obstruction. Chest 2018;153:618\u201329. https:\/\/doi.org\/10.1016\/j.chest.2017.11.016.","DOI":"10.1016\/j.chest.2017.11.016"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_057","doi-asserted-by":"crossref","unstructured":"Kraft, M, Djukanovic, R, Wilson, S, Holgate, ST, Martin, RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154:1505\u201310. https:\/\/doi.org\/10.1164\/ajrccm.154.5.8912772.","DOI":"10.1164\/ajrccm.154.5.8912772"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_058","doi-asserted-by":"crossref","unstructured":"Dolhnikoff, M, Da Silva, LFF, De Araujo, BB, Gomes, HAP, Fernezlian, S, Mulder, A, et al.. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol 2009;123:1090\u20137e1. https:\/\/doi.org\/10.1016\/j.jaci.2009.02.032.","DOI":"10.1016\/j.jaci.2009.02.032"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_059","doi-asserted-by":"crossref","unstructured":"De Magalhaes Simoes, S, Dos Santos, MA, Da Silva Oliveira, M, Fontes, ES, Fernezlian, S, Garippo, AL, et al.. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005;35:602\u201311. https:\/\/doi.org\/10.1111\/j.1365-2222.2005.02235.x.","DOI":"10.1111\/j.1365-2222.2005.02235.x"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_060","doi-asserted-by":"crossref","unstructured":"Kohno, N, Kyoizumi, S, Awaya, Y, Fukuhara, H, Yamakido, M, Akiyama, M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68\u201373. https:\/\/doi.org\/10.1378\/chest.96.1.68.","DOI":"10.1378\/chest.96.1.68"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_061","doi-asserted-by":"crossref","unstructured":"Kamiya, K, Watanabe, M, Kohno, M, Izumi, Y, Horinouchi, H, Kawamura, M, et al.. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. Respirology 2011;16:976\u201382. https:\/\/doi.org\/10.1111\/j.1440-1843.2011.02009.x.","DOI":"10.1111\/j.1440-1843.2011.02009.x"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_062","doi-asserted-by":"crossref","unstructured":"Takahashi, T, Munakata, M, Suzuki, I, Kawakami, Y. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1998;158:1294\u20138. https:\/\/doi.org\/10.1164\/ajrccm.158.4.9712003.","DOI":"10.1164\/ajrccm.158.4.9712003"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_063","doi-asserted-by":"crossref","unstructured":"Oyama, T, Kohno, N, Yokoyama, A, Hirasawa, Y, Hiwada, K, Oyama, H, et al.. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung 1997;175:379\u201385. https:\/\/doi.org\/10.1007\/pl00007584.","DOI":"10.1007\/PL00007584"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_064","doi-asserted-by":"crossref","unstructured":"Ohnishi, H, Yokoyama, A, Kondo, K, Hamada, H, Abe, M, Nishimura, K, et al.. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378\u201381. https:\/\/doi.org\/10.1164\/ajrccm.165.3.2107134.","DOI":"10.1164\/ajrccm.165.3.2107134"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_065","doi-asserted-by":"crossref","unstructured":"Uhal, BD, Rayford, H, Zhuang, J, Li, X, Laukka, J, Soledad-Conrad, V. Apoptosis-dependent acute lung injury and repair after intratracheal instillation of noradrenaline in rats. Exp Physiol 2003;88:269\u201375. https:\/\/doi.org\/10.1113\/eph8802523.","DOI":"10.1113\/eph8802523"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_066","unstructured":"Kohno, N. Serum marker KL-6\/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 1999;46:151\u20138."},{"key":"2024012315074075255_j_cclm-2022-1323_ref_067","doi-asserted-by":"crossref","unstructured":"Hirasawa, Y, Kohno, N, Yokoyama, A, Inoue, Y, Abe, M, Hiwada, K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 1997;17:501\u20137. https:\/\/doi.org\/10.1165\/ajrcmb.17.4.2253.","DOI":"10.1165\/ajrcmb.17.4.2253"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_068","doi-asserted-by":"crossref","unstructured":"Ishikawa, N, Hattori, N, Yokoyama, A, Kohno, N. Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012;50:3\u201313. https:\/\/doi.org\/10.1016\/j.resinv.2012.02.001.","DOI":"10.1016\/j.resinv.2012.02.001"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_069","doi-asserted-by":"crossref","unstructured":"Kuwana, M, Shirai, Y, Takeuchi, T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 2016;43:1825\u201331. https:\/\/doi.org\/10.3899\/jrheum.160339.","DOI":"10.3899\/jrheum.160339"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_070","doi-asserted-by":"crossref","unstructured":"Miyazaki, Y, Tsutsui, T, Inase, N. Treatment and monitoring of hypersensitivity pneumonitis. Expert Rev Clin Immunol 2016;12:953\u201362. https:\/\/doi.org\/10.1080\/1744666X.2016.1182426.","DOI":"10.1080\/1744666X.2016.1182426"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_071","doi-asserted-by":"crossref","unstructured":"Ogihara, T, Hirano, K, Morinobu, T, Kim, H-S, Ogawa, S, Hiroi, M, et al.. Plasma KL-6 predicts the development and outcome of bronchopulmonary dysplasia. Pediatr Res 2006;60:613\u20138. https:\/\/doi.org\/10.1203\/01.pdr.0000242361.47408.51.","DOI":"10.1203\/01.pdr.0000242361.47408.51"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_072","doi-asserted-by":"crossref","unstructured":"Ishikawa, N, Hattori, N, Kohno, N, Kobayashi, A, Hayamizu, T, Johnson, M. Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls. Int J Chron Obstruct Pulmon Dis 2015;10:185\u201392. https:\/\/doi.org\/10.2147\/COPD.S74557.","DOI":"10.2147\/COPD.S74557"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_073","doi-asserted-by":"crossref","unstructured":"Peng, D-H, Luo, Y, Huang, L-J, Liao, F-L, Liu, Y-Y, Tang, P, et al.. Correlation\u00a0of\u00a0Krebs von den Lungen-6 and fibronectin\u00a0with pulmonary fibrosis\u00a0in coronavirus disease 2019. Clin Chim Acta 2021;517:48\u201353. https:\/\/doi.org\/10.1016\/j.cca.2021.02.012.","DOI":"10.1016\/j.cca.2021.02.012"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_074","doi-asserted-by":"crossref","unstructured":"Imai, T, Takase, M, Takeda, S, Kougo, T. Serum KL-6 levels in pediatric\u00a0patients: reference values for children and levels in pneumonia, asthma, and measles patients. Pediatr Pulmonol 2002;33:135\u201341. https:\/\/doi.org\/10.1002\/ppul.10044.","DOI":"10.1002\/ppul.10044"},{"key":"2024012315074075255_j_cclm-2022-1323_ref_075","doi-asserted-by":"crossref","unstructured":"Bergantini, L, d\u2019Alessandro, M, Cameli, P, Bianchi, F, Sestini, P, Bargagli, E, et al.. Personalized approach of severe eosinophilic asthma patients treated with mepolizumab and benralizumab. Int Arch Allergy Immunol 2020;181:746\u201353. https:\/\/doi.org\/10.1159\/000508936.","DOI":"10.1159\/000508936"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1323\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T15:09:57Z","timestamp":1706022597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1323\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,4,4]]},"published-print":{"date-parts":[[2023,9,26]]}},"alternative-id":["10.1515\/cclm-2022-1323"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-1323","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}